Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.

Bittoni MA, Arunachalam A, Li H, Camacho R, He J, Zhong Y, Lubiniecki GM, Carbone DP.

Clin Lung Cancer. 2018 May 7. pii: S1525-7304(18)30099-8. doi: 10.1016/j.cllc.2018.04.017. [Epub ahead of print]

2.

IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DS, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680-4. doi: 10.1016/j.jtho.2018.05.030. [Epub ahead of print]

PMID:
29885479
3.

Safety of dose-reduced pemetrexed in patients with renal insufficiency.

Hill J, Vargo C, Smith M, Streeter J, Carbone DP.

J Oncol Pharm Pract. 2018 Jan 1:1078155218780507. doi: 10.1177/1078155218780507. [Epub ahead of print]

PMID:
29871545
4.

The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer.

Miller ED, Fisher JL, Haglund KE, Grecula JC, Xu-Welliver M, Bertino EM, He K, Shields PG, Carbone DP, Williams TM, Otterson GA, Bazan JG.

J Thorac Oncol. 2018 Mar;13(3):426-435. doi: 10.1016/j.jtho.2017.11.135. Epub 2018 Jan 8.

PMID:
29326090
5.

Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma.

Sharpnack MF, Chen B, Aran D, Kosti I, Sharpnack DD, Carbone DP, Mallick P, Huang K.

EBioMedicine. 2018 Jan;27:167-175. doi: 10.1016/j.ebiom.2017.12.005. Epub 2017 Dec 6.

6.

Blood-based biomarkers in lung cancer: prognosis and treatment decisions.

Xu-Welliver M, Carbone DP.

Transl Lung Cancer Res. 2017 Dec;6(6):708-712. doi: 10.21037/tlcr.2017.09.08. Review.

7.

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations.

Yamada T, Amann JM, Tanimoto A, Taniguchi H, Shukuya T, Timmers C, Yano S, Shilo K, Carbone DP.

Mol Cancer Ther. 2018 Jan;17(1):17-25. doi: 10.1158/1535-7163.MCT-17-0146. Epub 2017 Oct 27.

PMID:
29079711
8.

Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy.

Shukuya T, Patel S, Shane-Carson K, He K, Bertino EM, Shilo K, Otterson GA, Carbone DP.

J Thorac Oncol. 2018 Feb;13(2):e17-e19. doi: 10.1016/j.jtho.2017.09.1962. Epub 2017 Oct 5. No abstract available.

PMID:
28989037
9.

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer.

Wald P, Mo X, Barney C, Gunderson D, Haglund AK, Bazan J, Grecula J, Chakravarti A, Williams T, Carbone DP, Xu-Welliver M.

J Thorac Oncol. 2017 Dec;12(12):1779-1787. doi: 10.1016/j.jtho.2017.08.010. Epub 2017 Aug 24.

PMID:
28843360
10.

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

Abernethy AP, Arunachalam A, Burke T, McKay C, Cao X, Sorg R, Carbone DP.

PLoS One. 2017 Jun 23;12(6):e0178420. doi: 10.1371/journal.pone.0178420. eCollection 2017.

11.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators.

N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.

12.

Ibuprofen and fatal lung cancer: A brief report of the prospective results from the Third National Health and Nutrition Examination Survey (NHANES III).

Bittoni MA, Carbone DP, Harris RE.

Mol Clin Oncol. 2017 Jun;6(6):917-920. doi: 10.3892/mco.2017.1239. Epub 2017 May 5.

13.

Non-small cell lung cancer genomics around the globe: focus on ethnicity.

Araujo LH, Carbone DP.

J Thorac Dis. 2017 Apr;9(4):E392-E394. doi: 10.21037/jtd.2017.03.143. No abstract available.

14.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

15.

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.

Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN 1512 Investigators.

Lancet Oncol. 2016 Dec;17(12):1661-1671. doi: 10.1016/S1470-2045(16)30561-7. Epub 2016 Nov 4.

16.

A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.

Kaufman JM, Yamada T, Park K, Timmers CD, Amann JM, Carbone DP.

Cancer Res. 2017 Jan 1;77(1):153-163. doi: 10.1158/0008-5472.CAN-16-1639. Epub 2016 Nov 7.

17.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.

Shukuya T, Mori K, Amann JM, Bertino EM, Otterson GA, Shields PG, Morita S, Carbone DP.

J Thorac Oncol. 2016 Nov;11(11):1927-1939. doi: 10.1016/j.jtho.2016.07.017. Epub 2016 Aug 3.

18.

Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims Analysis.

Lokhandwala T, Bittoni MA, Dann RA, D'Souza AO, Johnson M, Nagy RJ, Lanman RB, Merritt RE, Carbone DP.

Clin Lung Cancer. 2017 Jan;18(1):e27-e34. doi: 10.1016/j.cllc.2016.07.006. Epub 2016 Jul 21.

PMID:
27530054
19.

Defining a standard set of patient-centred outcomes for lung cancer.

Mak KS, van Bommel AC, Stowell C, Abrahm JL, Baker M, Baldotto CS, Baldwin DR, Borthwick D, Carbone DP, Chen AB, Fox J, Haswell T, Koczywas M, Kozower BD, Mehran RJ, Schramel FM, Senan S, Stirling RG, van Meerbeeck JP, Wouters MW, Peake MD; Lung Cancer Working Group of ICHOM.

Eur Respir J. 2016 Sep;48(3):852-60. doi: 10.1183/13993003.02049-2015. Epub 2016 Jul 7.

20.

The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.

Matsunaga Y, Adachi Y, Sasaki Y, Koide H, Motoya M, Nosho K, Takagi H, Yamamoto H, Sasaki S, Arimura Y, Tokino T, Carbone DP, Imai K, Shinomura Y.

Mol Carcinog. 2017 Feb;56(2):515-526. doi: 10.1002/mc.22513. Epub 2016 Jun 23.

PMID:
27312358
21.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR.

J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.

22.

Treatment Patterns for Advanced Non-Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice.

McKay C, Burke T, Cao X, Abernethy AP, Carbone DP.

Clin Lung Cancer. 2016 Sep;17(5):449-460.e7. doi: 10.1016/j.cllc.2016.03.008. Epub 2016 Mar 29.

PMID:
27157534
23.

Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature.

Siegele BJ, Shilo K, Chao BH, Carbone DP, Zhao W, Ioffe O, Franklin WA, Edelman MJ, Aisner DL.

Lung Cancer. 2016 May;95:65-72. doi: 10.1016/j.lungcan.2016.02.012. Epub 2016 Feb 26. Review.

24.

Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-38. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.

25.

Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer.

Shukuya T, Carbone DP.

J Thorac Oncol. 2016 Jul;11(7):976-88. doi: 10.1016/j.jtho.2016.02.015. Epub 2016 Mar 2. Review.

26.

Aquaporin 11 variant associates with kidney disease in type 2 diabetic patients.

Choma DP, Vanacore R, Naylor H, Zimmerman IA, Pavlichenko A, Pavlichenko A, Foye L, Carbone DP, Harris RC, Dikov MM, Tchekneva EE.

Am J Physiol Renal Physiol. 2016 Mar 1;310(5):F416-25. doi: 10.1152/ajprenal.00295.2015. Epub 2015 Dec 30.

27.

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.

Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, Stegmaier P, McNulty M, Karachaliou N, Rosell R, Bepler G, Carbone DP, Chakravarti A.

Clin Cancer Res. 2016 May 15;22(10):2396-404. doi: 10.1158/1078-0432.CCR-15-1468. Epub 2015 Dec 15.

28.

Impact of Pre-Analytical Variables on Cancer Targeted Gene Sequencing Efficiency.

Araujo LH, Timmers C, Shilo K, Zhao W, Zhang J, Yu L, Natarajan TG, Miller CJ, Yilmaz AS, Liu T, Amann J, Lapa E Silva JR, Ferreira CG, Carbone DP.

PLoS One. 2015 Nov 25;10(11):e0143092. doi: 10.1371/journal.pone.0143092. eCollection 2015.

29.

PDL1 Regulation by p53 via miR-34.

Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW.

J Natl Cancer Inst. 2015 Nov 17;108(1). pii: djv303. doi: 10.1093/jnci/djv303. Print 2016 Jan.

30.

Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.

Thounaojam MC, Dudimah DF, Pellom ST Jr, Uzhachenko RV, Carbone DP, Dikov MM, Shanker A.

Oncotarget. 2015 Oct 20;6(32):32439-55. doi: 10.18632/oncotarget.5857.

31.

Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy.

Biktasova AK, Dudimah DF, Uzhachenko RV, Park K, Akhter A, Arasada RR, Evans JV, Novitskiy SV, Tchekneva EE, Carbone DP, Shanker A, Dikov MM.

Cancer Res. 2015 Nov 15;75(22):4728-41. doi: 10.1158/0008-5472.CAN-14-1154. Epub 2015 Sep 24.

32.

Promise of Immunotherapy in Lung Cancer.

Shanker A, Dikov MM, Carbone DP.

Prog Tumor Res. 2015;42:95-109. doi: 10.1159/000437179. Epub 2015 Sep 4. Review.

PMID:
26383097
33.

Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis.

Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP.

J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650.

34.

Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.

Yamada T, Amann JM, Fukuda K, Takeuchi S, Fujita N, Uehara H, Iwakiri S, Itoi K, Shilo K, Yano S, Carbone DP.

Cancer Res. 2015 Oct 1;75(19):4188-97. doi: 10.1158/0008-5472.CAN-15-0858. Epub 2015 Aug 20.

35.

Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L.

J Thorac Oncol. 2015 Jul;10(7):974-84. doi: 10.1097/JTO.0000000000000551. Review.

36.

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.

Whang YM, Park SI, Trenary IA, Egnatchik RA, Fessel JP, Kaufman JM, Carbone DP, Young JD.

Oncogene. 2016 Feb 18;35(7):856-66. doi: 10.1038/onc.2015.140. Epub 2015 Jun 29.

37.

Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.

Araujo LH, Timmers C, Bell EH, Shilo K, Lammers PE, Zhao W, Natarajan TG, Miller CJ, Zhang J, Yilmaz AS, Liu T, Coombes K, Amann J, Carbone DP.

J Clin Oncol. 2015 Jun 10;33(17):1966-73. doi: 10.1200/JCO.2014.59.2444. Epub 2015 Apr 27.

38.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR.

J Clin Oncol. 2015 Jun 20;33(18):2004-12. doi: 10.1200/JCO.2014.58.3708. Epub 2015 Apr 20.

39.

Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.

Huang Y, Carbone DP.

Biochim Biophys Acta. 2015 Apr;1855(2):193-201. doi: 10.1016/j.bbcan.2015.01.003. Epub 2015 Jan 15. Review.

PMID:
25598052
40.

Non-small-cell lung cancer.

Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R.

Nat Rev Dis Primers. 2015 May 21;1:15009. doi: 10.1038/nrdp.2015.9. Review.

PMID:
27188576
41.

EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.

Arasada RR, Amann JM, Rahman MA, Huppert SS, Carbone DP.

Cancer Res. 2014 Oct 1;74(19):5572-84. doi: 10.1158/0008-5472.CAN-13-3724. Epub 2014 Aug 14.

42.

Highlights from the latest articles in lung cancer personalized medicine.

Rivas-Perez H, Carbone DP, Nana-Sinkam SP.

Per Med. 2014 Jun;11(4):377-379. doi: 10.2217/pme.14.18. No abstract available.

PMID:
29783480
43.

LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.

Kaufman JM, Amann JM, Park K, Arasada RR, Li H, Shyr Y, Carbone DP.

J Thorac Oncol. 2014 Jun;9(6):794-804. doi: 10.1097/JTO.0000000000000173.

44.

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K.

Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9.

45.

Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer.

Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L.

J Thorac Oncol. 2014 Apr;9(4):559-62. doi: 10.1097/JTO.0000000000000079.

46.

An era of lung cancer iconoclasts.

Carbone DP.

J Thorac Oncol. 2014 Apr;9(4):436-7. doi: 10.1097/JTO.0000000000000121. No abstract available.

47.

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.

Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, Schiller J, Villalona-Calero MA, Meyerson M, Carbone DP.

J Clin Invest. 2014 Apr;124(4):1582-6. doi: 10.1172/JCI72763. Epub 2014 Feb 24.

48.

Reducing lung cancer mortality: 2014 update.

Horn L, Carbone DP.

Semin Oncol. 2014 Feb;41(1):3-4. doi: 10.1053/j.seminoncol.2013.12.004. Epub 2013 Dec 12. No abstract available.

PMID:
24565576
49.

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE.

BMC Cancer. 2014 Jan 4;14:5. doi: 10.1186/1471-2407-14-5.

50.

The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma.

Adachi Y, Ohashi H, Imsumran A, Yamamoto H, Matsunaga Y, Taniguchi H, Nosho K, Suzuki H, Sasaki Y, Arimura Y, Carbone DP, Imai K, Shinomura Y.

Tumour Biol. 2014 Feb;35(2):973-85. doi: 10.1007/s13277-013-1131-2. Epub 2013 Sep 13.

PMID:
24026884

Supplemental Content

Loading ...
Support Center